Mucormycosis medications: a patent review

References

• Binder U, Maurer E, Lass-Flörl C. Mucormycosis-from the pathogens to the disease. Clin Microbiol Infect. 2014;20(Suppl 6):60–66.
   PubMedGoogle Scholar
• Hernández JL, Buckley CJ. Mucormycosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Jan. 2020.
   Google Scholar
• Thornton CR. Detection of the ‘big five’ mold killers of humans: aspergillus, fusarium, lomentospora, scedosporium, and mucormycetes. Adv Appl Microbiol. 2020;110:1–61.
   PubMed Web of Science ®Google Scholar
• Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20(Suppl 6):74–81.
   PubMed Web of Science ®Google Scholar
• Ananthaneni AR, Undavalli SB, Velagapudi RP, et al. Mucormycosis: an atrocious mate of patients with diabetes. BMJ Case Rep. 2013;2013(may02 1):bcr2013009600. .
   PubMedGoogle Scholar
• Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.
   PubMedGoogle Scholar
• Serris A, Danion F, Lanternier F. Disease entities in mucormycosis. J Fungi (Basel). 2019;5(1):23.
   PubMedGoogle Scholar
• Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–1224.
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
   PubMed Web of Science ®Google Scholar
• Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):S93–S101.
   PubMedGoogle Scholar
• Chen SCA, Slavin MA. Management of Mucorales Infections in Transplant Patients. In: Morris M, Kotton C, Wolfe C, editors. Emerging Transplant Infections. Cham: Springer; 2020. p. 1–30.
   Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421. .
   PubMed Web of Science ®Google Scholar
• Walker RC, Zeuli JD, Temesgen Z. Isavuconazonium sulfate for the treatment of fungal infection. Drugs Today (Barc). 2016;52(1):7–16.
   PubMed Web of Science ®Google Scholar
• Brunet K, Rammaert B. Mucormycosis treatment: recommendations, latest advances, and perspectives. J Mycol Med. 2020;30(3):101007.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Birtel A, Vehreschild MJ, et al. Mucormycosis treated with posaconazole: a review of 96 case reports. Crit Rev Microbiol. 2013;39(3):310–324. .
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–569.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Wurster S, Beyda ND, et al. Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. Diagn Microbiol Infect Dis. 2019;95(3):114861. .
   PubMed Web of Science ®Google Scholar
• Ribeiro EF, dos Santos VM, Paixão GT, et al. Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen. Mycopathologia. 2013;175(3–4):295–300. .
   PubMed Web of Science ®Google Scholar
• Fukuda H, Hayase T, Mizuguchi E, et al. N-substituted carbamoyloxyalkyl-azolium derivatives. US7459561B2. 2008.
   Google Scholar
• Olin M Amphotericins, their salts and method of manufacture. GB795482A. 1958.
   Google Scholar
• Bennett F, Ganguly AK, Girijavallabhan VM, et al. Tetrahydrofuran antifungals. US5661151A. 1997.
   Google Scholar
• Acklin P, Lattmann R Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators. US6465504B1. 2002.
   Google Scholar
• Ray SJ, Richardson K Triazole antifungal agents. US5567817A. 1996.
   Google Scholar
• Liu L, New antifungal macrocyclic polyene compounds. CN112175029A. 2021
   Google Scholar
• Covel J, Shaw KJ, Trzoss M, et al. Heterocycle substituted pyridine derivative antifungal agents. WO2020247804A1. 2020.
   Google Scholar
• Covel J, Shaw KJ, Trzoss M, et al. Heterocycle substituted pyridine derivative antifungal agents. WO2019113542A1. 2019.
   Google Scholar
• Barbey S, Bougeret C, Briand JF, et al. 1,2,4-Thiadiazole derivatives antifungal compounds, compositions containing said compounds and the use thereof. WO2007012724A1. 2007.
   Google Scholar
• Buchan ZA, Gustafson GD, Hoekstra WJ, et al. Metalloenzyme inhibitor compounds as fungicides. WO2015160665A1. 2015.
   Google Scholar
• Buchan ZA, Gustafson GD, Hoekstra WJ, et al. Metalloenzyme inhibitor compounds as fungicides. WO2015160664A1. 2015.
   Google Scholar
• Wasan EK, Wasan KM Stabilized formulation for oral administration of therapeutic agents and related methods. US8673866B2. 2014.
   Google Scholar
• Wasan EK, Wasan KM Formulations for the oral administration of therapeutic agents and related methods. US8592382B2. 2013.
   Google Scholar
• Betancourt A, Hnik P, Thibert R Solid oral formulations of amphotericin B. WO2020028508A1. 2020.
   Google Scholar
• Bruno V, Ibrahim A, Watkins T Methods of treating or preventing mucormycosis. WO2020006438A1. 2020.
   Google Scholar
• Chawla L, Tidmarsh G Methods of administering hepcidin. US20190240292A1. 2019.
   Google Scholar
• Av-Gay Y, Greenberg D, Tal A Nitric oxide inhalation therapy for infants with bronchiolitis. US2020246573A1. 2020.
   Google Scholar
• Dessen A, Hill KE, Klinkenberg G, et al. use of alginate oligomers to enhance the effects of antifungal agents. US2015126467A1. 2015.
   Google Scholar
• Edwards JE, Ibrahim AS, Spellberg BJ Combi compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent. AU2007272781B2. 2012.
   Google Scholar
• Burnie JP Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies. EP1267925B1. 2007.
   Google Scholar
• Clackson TP, Gilman MZ, Holt DA, et al. Materials and method for treating or preventing pathogenic fungal infection. US6258823B1. 2001.
   Google Scholar
• Gray PW Chitinase materials and methods. US6372212B1. 2002.
   Google Scholar
• Duncan V, O’Neil D Use of cysteamine in treating infections caused by yeasts/moulds. AU2015323566B2. 2018.
   Google Scholar
• Catherine H, Gopal K, Leonore WL, et al. Particulate-stabilized injectable pharmaceutical compositions of posaconasol. BRPI0510417A. 2007.
   Google Scholar
• Keith CT, Lehar J, Serbedzija GN, et al. Combinations for the treatment of fungal infections. WO2005082054A2. 2005.
   Google Scholar
• Auspitz BA, Johansen LM, Serbedzija GN Combinations for the treatment of fungal infections. WO2005053613A2. 2005.
   Google Scholar
• Wu H Pharmaceutical composition and applications thereof. CN104739834A. 2015.
   Google Scholar
• Chevion M, Vinokur V Compositions and methods for treatment of iron overload. WO2019202584A1. 2019.
   Google Scholar
• Auspitz BA, Keith C, Nichols MJ, et al. Combinations for the treatment of fungal infections. WO03066049A1. 2003.
   Google Scholar
• Coates A, Hu Y Methods and compositions for treating microbial infection using pyrroloquinone US9789101B2. 2017.
   Google Scholar
• Coates A, Hu Y A therapeutic agent for microbial infection comprising a combination of nordihydroguaiaretic acid and aminoglycoside. JP6282337B2. 2018.
   Google Scholar
• Coates A, Hu Y Combination and use. US10335454B2. 2019.
   Google Scholar
• Coates A, Hu Y Formulation. WO2017098274A1. 2017.
   Google Scholar
• Draper M, Nelson ML Substituted tetracycline compounds as synergistic antifungal agents. WO2002072031A2. 2002.
   Google Scholar
• Burnie JP Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies. WO0176627A1. 2001.
   Google Scholar
• Edwards JE, Fu Y, Ibrahim AS, et al. Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases. US8444985B2. 2013.
   Google Scholar
• Edwards JE, Filler S, Fu Y, et al. Mammalian receptors as targets for antibody and active vaccination therapy against mold infections. US9259467B2. 2016.
   Google Scholar
• Edwards JE, Filler S, Fu Y, et al. immunotherapy and diagnosis of mucormycosis using CotH. US9279002B2. 2016.
   Google Scholar
• Brocchini S, Choi JW, Godwin A, et al. Complexes having adjuvant activity. EP1701741B1. 2008.
   Google Scholar
• Brix L, Pedersen H, Schøller J Molecular vaccines for infectious disease. US10369204B2. 2019.
   Google Scholar
• Cojocaru GS, Dassa L, Kliger Y, et al. VSTM5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases. US2016272707A1. 2016.
   Google Scholar
• Laskavyj VN, Malakhova EA, Panferov VI Combined vaccine for rabbit visceral mycoses. RU2352355C1. 2009.
   Google Scholar
• Alanio A, Dromer F, Janbon G, et al. Recombinant aspartyl protease antigen or antibody thereto for use in immunotherapy of fungal diseases. WO2017109028A1. 2017.
   Google Scholar
• Zhang G, Zhang H Medical plants synergist having antifungal activity and drug tolerance of reversion azole antifungal agents. CN101032486B. 2011.
   Google Scholar
• Divi SB, Medasani M Picrorhiza extract for prevention, elimination and treatment of infection diseases; United States Patent. US9603885B2. 2017.
   Google Scholar
• Divi SB, Medasani M Picrorhiza extract for prevention, elimination and treatment of infection diseases. US9125921B2. 2015.
   Google Scholar
• Armstrong ET Anti-infective mangrove extract against viruses, bacteria and fungi. US20120040033A1. 2012.
   Google Scholar
• Divi SB, Medasani M Picrorhiza kurroa extract for prevention, elimination and treatment of DNA based viruses in humans and in biotech industry. US9433656B2. 2016.
   Google Scholar
• Coates A, Hu Y Antimicrobial combinations and their use in the treatment of microbial infection. US2019111067A1. 2019.
   Google Scholar
• Wenkang YW Chinese herbal medicine preparation for preventing and treating aquatic product animal mycoses, its preparation process and use. CN101011547A. 2007.
   Google Scholar
• Chen H, Lu D, Tang X, et al. Chinese herbal medicine preparation for controlling fish hydromycosis and application thereof. CN109602873A. 2019.
   Google Scholar
• Chen J, Shi D Chinese herba preparation for treating mucormycosis of Cyclemys trifasciata and preparation method of Chinese herbal preparation. CN104873863A. 2015.
   Google Scholar
• Chen J, Shi D Feed for treating mucormycosis of Cyclemys trifasciata and preparation method of feed. CN104872438A. 2015.
   Google Scholar
• Bloch I, Katz C Combination therapies including human chitinase (chit1) for the treatment of systemic fungal infection. WO2018078626A1. 2018.
   Google Scholar
• O’Neil D Use. US2016106689A1. 2016.
   Google Scholar
• Lee PS, Stossel TP Use of gelsolin to treat infections. AU2011218617B2. 2014.
   Google Scholar
• Cavanagh H Anti-fungal treatments. WO2006108215A1. 2006.
   Google Scholar
• Koo S, Marty FM Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi. US20190183887A1. 2019.
   Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–934.
   PubMed Web of Science ®Google Scholar
• Dekkers BGJ, Bakker M, van der Elst KCM, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10(2)51–61.
   PubMed Web of Science ®Google Scholar
• Kovanda LL, Maher R, Hope WW. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. Expert Rev Clin Pharmacol. 2016;9(7):887–897.
   PubMed Web of Science ®Google Scholar
• Beswick MC, Coates A, Cramp SM, et al. use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms. WO2008142384A1. 2008.
   Google Scholar
• Hurley TB, Peukert S, Wattanasin S Inhibitors of undecaprenyl pyrophosphate synthase. WO2008014311A2. 2008.
   Google Scholar
• Hoekstra WJ, Yates CM Metalloenzyme inhibitor compounds. WO2013090210A1. 2013.
   Google Scholar
• Hoekstra WJ, Yates CM Metalloenzyme inhibitor compounds. WO2014201161A1. 2014.
   Google Scholar
• Brünner N, Ingmer H, Vestergaard M Compounds for treatment of microbial infection. WO2020079051A1. 2020.
   Google Scholar
• Chirkin E, Nantermet P, Roemer T, et al. Bifunctional antifungal agents and methods of treating fungal infection. WO2018035424A1. 2018.
   Google Scholar
• Hoekstra WJ, Shaver SR, Yates CM Metalloenzyme inhibitor compounds. WO2017117393A1. 2017.
   Google Scholar
• Hoekstra WJ, Rafferty SW, Schotzinger RJ Metalloenzyme inhibitor compounds. WO2013109998A1. 2013.
   Google Scholar
• Bahadoor A, Castro AC, Chan LK, et al. Tetrazolones as inhibitors of fatty acid synthase. WO2011140190A1. 2011.
   Google Scholar
• Bahadoor A, Castro AC, Chan LK, et al. Triazoles as inhibitors of fatty acid synthase. WO2011140296A1. 2011.
   Google Scholar
• Hurley TB, Lee K, Peukert S, et al. Inhibitors of undecaprenyl pyrophosphate synthase. WO2008014307A2. 2008.
   Google Scholar
• Del-Poeta M, Haranahalli K, Lazzarini C, et al. Anti-fungals compounds targeting the synthesis of fungal sphingolipids. WO2018232298A1. 2018.
   Google Scholar
• Bhagwat SS, Jafri MA, Patel MV Efflux pump inhibitors. WO2011101710A1. 2011.
   Google Scholar
• Balkovec JM, Borchardt A, James KD Antifungal agents. WO2016201283A1. 2016.
   Google Scholar
• Draper M, Nelson ML Substituted tetracycline compounds as antifungal agents. WO2002072022A2. 2002.
   Google Scholar
• Liu C, Liu CY, Yang S, et al. Boron containing compounds and their uses. WO2020123881A1. 2020.
   Google Scholar
• Beck PH, Brown MB, Clark DE, et al. use of pyrroloquinoline compounds to kill clinically latent microorganisms. WO2007054693A1. 2007.
   Google Scholar
• James KDJ, Laudeman CP, Malkar NB, et al. Antifungal agents and uses thereof. WO2012119065A2. 2012.
   Google Scholar
• Bommer JC, Prestwich G, Testa C Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth. WO2010014728A1. 2010.
   Google Scholar
• Coates A, Cramp SM, Dyke HJ, et al. Antimicrobial compounds based upon 4-aminoquinoline. WO2008117079A1. 2008.
   Google Scholar
• Hoekstra WJ, Rafferty SW, Schotzinger RJ Metalloenzyme inhibitor compounds. WO2011133875A2. 2011.
   Google Scholar